Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database.
Clinical remission
patients’ reported outcome
quality of life
rheumatoid arthritis
Journal
Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226
Informations de publication
Date de publication:
13 Apr 2023
13 Apr 2023
Historique:
received:
09
02
2022
accepted:
01
06
2022
medline:
17
4
2023
pubmed:
3
6
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
To explore patient-reported outcomes (PROs) related to quality of life (QOL) in patients with rheumatoid arthritis (RA) who achieved clinical remission. In the Institute of Rheumatology, Rheumatoid Arthritis dataset, RA patients >18 years old who met the simplified disease activity index (SDAI) remission criteria in April 2017 were enrolled in this analysis. Pain-visual analogue scale (pain-VAS) (0-100 mm), patient's global assessment of disease activity (Pt-GA; 0-100 mm), Japanese version of the Health Assessment Questionnaire, duration of morning joint stiffness, and fatigue [Checklist Individual Strength 8R (CIS)] were the tools used to evaluate PROs. To assess the contribution of each PRO to the European QOL-5 Dimensions-5 Level (EQ-5D-5L) score, an analysis of variance was conducted. Among the 2443 patients with remission, the mean EQ-5D-5L was 0.9. The mean pain-VAS and Pt-GA were 7.2 and 7.4, respectively. Factors that significantly contributed to the EQ-5D-5L were pain-VAS (48.8%), CIS score (18.1%), and Pt-GA (15.6%). Around 82.5% of the variance in EQ-5D-5L was explained by the three PROs. This study demonstrated that pain-VAS, CIS, and Pt-GA were significant contributors to the EQ-5D-5L score in patients with RA who achieved the simplified disease activity index remission criteria.
Identifiants
pubmed: 35652691
pii: 6598788
doi: 10.1093/mr/roac053
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
496-502Informations de copyright
© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.